Overview

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.
Phase:
Phase 3
Details
Lead Sponsor:
Santen Pharmaceutical Co., Ltd.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions